{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T15:12:33Z","timestamp":1788880353765,"version":"build-2803163510"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T00:00:00Z","timestamp":1788825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nephrol."],"abstract":"<jats:p>Anemia is a common and clinically significant complication of chronic kidney disease (CKD), contributing to impaired quality of life, increased cardiovascular risk, and higher mortality. Although erythropoiesis-stimulating agents (ESAs) remain the cornerstone of anemia management, conventional short- and intermediate-acting ESAs are associated with frequent dosing requirements, treatment burden, and variability in haemoglobin (Hb) control. Methoxy polyethylene glycol epoetin beta (MPG-EPO; PegEPO), a long-acting ESA with an extended half-life, enables less frequent administration and may offer advantages in Hb stabilization, treatment adherence, and patient convenience. Despite evidence supporting its efficacy and safety, the utilization of PegEPO in India remains limited. To provide practical guidance for the use of PegEPO in Indian clinical practice, a panel of 12 experienced Indian nephrologists participated in a three round modified Delphi consensus process. A comprehensive review of the available literature informed the development of consensus statements covering key domains, including patient selection, treatment initiation and dose adjustment, iron management, conversion from other ESAs, Hb targets and monitoring, safety considerations, and economic aspects of therapy. Consensus was achieved through iterative rounds of expert evaluation and discussion. The expert panel agreed that PegEPO offers efficacy and safety comparable to conventional ESAs in patients with CKD-associated anemia while providing additional advantages such as reduced dosing frequency, improved Hb stability, and the potential to enhance treatment adherence. The panel also identified practical considerations for optimizing PegEPO use in both dialysis-dependent and non-dialysis-dependent CKD populations within the Indian healthcare setting. This modified Delphi consensus provides evidence-informed, expert-driven recommendations to support individualized and pragmatic use of PegEPO in routine clinical practice. However, these statements represent expert consensus and are not intended as clinical guidelines; therefore, they should be adapted based on individual patient context and local clinical practice.<\/jats:p>","DOI":"10.3389\/fneph.2026.1864394","type":"journal-article","created":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:53:35Z","timestamp":1788879215000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world use of pegylated erythropoietin in CKD-related anemia: an Indian modified Delphi consensus"],"prefix":"10.3389","volume":"6","author":[{"given":"Vijay","family":"Kher","sequence":"first","affiliation":[{"name":"Chairman, Nephrology, Epitome Kidney Urology Institute & Lions Hospital B-Block, Khizarabad Bhagol, New Friends Colony","place":["New Delhi, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jatin","family":"Kothari","sequence":"additional","affiliation":[{"name":"Principal Director of Nephrology, Chief Consultant- Kidney Transplantation, Nanavati Max Hospital, Mumbai","place":["Maharashtra, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra","family":"Kumar","sequence":"additional","affiliation":[{"name":"Chairman, Department of Renal Sciences & Transplant Medicine, Accord Superspeciality Hospital, Budena Village, Sector 86, Faridabad","place":["Haryana, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjay","family":"Srinivasa","sequence":"additional","affiliation":[{"name":"Dr. Sanjay \u2018s Center for Kidney and Diabetes, Yelahanka, Bengaluru","place":["Karnataka, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kedlaya","sequence":"additional","affiliation":[{"name":"Professor and Head, Dept of Nephrology, St Johns Medical College Hospital","place":["Bengaluru, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivalingam","family":"M","sequence":"additional","affiliation":[{"name":"HOD, Department of Nephrology, Sundaram Medical Foundation (SMF)","place":["Chennai, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rammohan","family":"Bhat","sequence":"additional","affiliation":[{"name":"Director, Institute of Renal Sciences - Kauvery Hospital","place":["Bangalore, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh","family":"Nair","sequence":"additional","affiliation":[{"name":"Prof and Head, Department of Nephrology and Kidney Transplantation, Amrita Institute of Medical Sciences","place":["Kochi, Kerala, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mallikarjuna","family":"HM","sequence":"additional","affiliation":[{"name":"Consultant Nephrologist & Transplant physician, Sagar Hospitals DSI","place":["Bengaluru, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reetesh","family":"Sharma","sequence":"additional","affiliation":[{"name":"Chairman, Nephrology & Kidney Transplant, Yatharth Superspeciality Hospital, Sector 20","place":["Faridabad, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay Kumar","family":"Sinha","sequence":"additional","affiliation":[{"name":"Senior Director, Nephrology & Kidney Transplant, Max Superspeciality Hospital, Noida Sector 128","place":["Noida, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sreedhara","family":"C. G.","sequence":"additional","affiliation":[{"name":"Consultant Nephrologist, Institute of Nephro-Urology","place":["Bengaluru, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay Kumar","family":"Sharma","sequence":"additional","affiliation":[{"name":"Medical Affairs, Intas Pharmaceuticals Limited, Corporate House, S. G. Highway, Thaltej, Ahmedabad","place":["Gujarat, India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iain C.","family":"Macdougall","sequence":"additional","affiliation":[{"name":"Professor (Retired), Clinical Nephrology, King\u2019s College Hospital","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2147\/IJNRD.S23447","article-title":"Methoxy polyethylene glycol-epoetin beta for anemia with chronic kidney disease","volume":"5","author":"Ohashi","year":"2012","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/nep.70002","article-title":"Prevalence and treatment patterns of anaemia in individuals with chronic kidney disease across Asia: a systematic review and meta-analysis","volume":"30","author":"Kim","year":"2025","journal-title":"Nephrol (Carlton)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-14-114","article-title":"Epidemiology and risk factors of chronic kidney disease in India: results from the SEEK study","volume":"14","author":"Singh","year":"2013","journal-title":"BMC Nephrol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.25259\/IJN_156_2025","article-title":"Anemia of chronic kidney disease in India: consensus guidelines of the Indian Society of Nephrology","volume":"35","author":"Bansal","year":"2025","journal-title":"Indian J Nephrol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad250","article-title":"Anaemia in CKD\u2014treatment standard","volume":"39","author":"Macdougall","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"B6","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2025.06.006","article-title":"KDIGO 2026 clinical practice guideline for the management of anemia in chronic kidney disease (CKD)","volume":"109","year":"2026","journal-title":"Kidney Int"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-1755.2005.00532.x","article-title":"Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin","volume":"68","author":"Fishbane","year":"2005","journal-title":"Kidney Int"},{"key":"B8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s12325-020-01524-6","article-title":"Burden of anemia in chronic kidney disease: beyond erythropoietin","volume":"38","author":"Hanna","year":"2021","journal-title":"Adv Ther"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1159\/000534070","article-title":"Continuous erythropoietin receptor activator for the treatment of chronic dialysis patients with renal anemia: NAVIGO trial","volume":"148","author":"Nowicki","year":"2024","journal-title":"Nephron"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.5958\/0974-360X.2017.00691.6","article-title":"A prospective study on efficacy of Mircera for treating anemia associated with chronic kidney disease","volume":"10","author":"Girisha","year":"2017","journal-title":"Res J Pharm Technol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.18203\/2320-6012.ijrms20232411","article-title":"Effectiveness of PegEPO in renal anaemia patients on dialysis: a multicentre observational study","volume":"11","author":"Mahesh","year":"2023","journal-title":"Int J Res Med Sci"},{"key":"B12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/ncpneph0655","article-title":"Mechanisms of disease: erythropoietin resistance in patients with both heart and kidney failure","volume":"4","author":"Van der Putten","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfac058","article-title":"Use of erythropoiesis-stimulating agents in children with chronic kidney disease: a systematic review","volume":"15","author":"Bruce","year":"2022","journal-title":"Clin Kidney J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1159\/000321486","article-title":"Conversion of darbepoetin to low doses of CERA maintains hemoglobin levels in non-dialysis CKD patients","volume":"30","author":"Minutolo","year":"2010","journal-title":"Blood Purif"},{"key":"B15","first-page":"S1","article-title":"Comparative clinical efficacy and safety of Erypeg\u00ae in adult CKD patients not on dialysis","volume":"26","author":"Mehta","year":"2016","journal-title":"Indian J Nephrol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000490202","article-title":"Patterns of erythropoiesis-stimulating agent use in European hemodialysis patients","volume":"140","author":"Fuller","year":"2018","journal-title":"Nephron"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0001442020","article-title":"Management of anemia in nondialysis chronic kidney disease","volume":"1","author":"Guedes","year":"2020","journal-title":"Kidney360"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s40620-022-01475-x","article-title":"Prevalence, incidence, and treatment of anaemia in non-dialysis CKD: a real-world study","volume":"36","author":"Minutolo","year":"2023","journal-title":"J Nephrol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2023.100677","article-title":"Iron-deficiency anemia in CKD: a narrative review","volume":"5","author":"Hain","year":"2023","journal-title":"Kidney Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13702","article-title":"Poor recognition and undertreatment of anemia in chronic kidney disease","volume":"294","author":"Xu","year":"2023","journal-title":"J Intern Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.4103\/1319-2442.265471","article-title":"Etiological spectrum of anemia in non-dialysis-dependent CKD","volume":"30","author":"Vikrant","year":"2019","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-022-02367-z","article-title":"Preferences for anaemia treatment attributes among patients with nondialysis CKD","volume":"40","author":"Alexandre","year":"2023","journal-title":"Adv Ther"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfr160","article-title":"C.E.R.A. once every 4 weeks corrects anaemia in CKD patients not on dialysis","volume":"26","author":"Roger","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.00480107","article-title":"C.E.R.A. corrects anemia in CKD not on dialysis","volume":"3","author":"Macdougall","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfn324","article-title":"Intravenous C.E.R.A. maintains stable haemoglobin levels in patients on dialysis previously treated with darbepoetin alfa: results from STRIATA, a randomized phase III study","volume":"23","author":"Canaud","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61599-2","article-title":"Intravenous CERA for hemoglobin control in dialysis patients","volume":"370","author":"Levin","year":"2007","journal-title":"Lancet"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.03631006","article-title":"Once-monthly subcutaneous C.E.R.A. maintains stable hemoglobin control in dialysis patients","volume":"2","author":"Sulowicz","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfu079","article-title":"Once-monthly CERA for haemoglobin maintenance in haemodialysis patients","volume":"7","author":"Duman","year":"2014","journal-title":"Clin Kidney J"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.10358","article-title":"Erythropoietin administration in CKD anemia: subcutaneous or intravenous","volume":"12","author":"Shahab","year":"2020","journal-title":"Cureus"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2007.01357.x","article-title":"Chronic anemia and fatigue in elderly patients","volume":"55","author":"Agnihotri","year":"2007","journal-title":"J Am Geriatr Soc"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcrp.2023.200220","article-title":"ESAs and cardiovascular mortality: a meta-analysis","volume":"19","author":"Karimi","year":"2023","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1159\/000350151","article-title":"Conversion from short-acting ESA to CERA in predialysis CKD","volume":"37","author":"Choi","year":"2013","journal-title":"Kidney Blood Press Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s11255-014-0800-4","article-title":"Beneficial dose conversion after switching to C.E.R.A.: MINERVA study","volume":"46","author":"Cases","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12882-025-04115-1","article-title":"UK kidney association clinical practice guideline: update of anaemia of chronic kidney disease","volume":"26","author":"Bhandari","year":"2025","journal-title":"BMC Nephrol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.xkme.2020.08.002","article-title":"ESA hyporesponsiveness and adverse outcomes","volume":"2","author":"Wish","year":"2020","journal-title":"Kidney Med"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2023.06.004","article-title":"Infectious risk and hemoglobin variability in hemodialysis","volume":"8","author":"Nishi","year":"2023","journal-title":"Kidney Int Rep"},{"key":"B37","article-title":"Comparative effects of pegylated erythropoietin and darbepoetin alfa on erythropoietin hyporesponsive anemia of patients with chronic kidney disease on maintenance hemodialysis","volume":"69","author":"Nand","year":"2021","journal-title":"J Assoc Physicians India"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2008.524","article-title":"Maintenance of target hemoglobin in stable hemodialysis patients","volume":"74","author":"Portol\u00e9s","year":"2008","journal-title":"Kidney Int"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1159\/000521162","article-title":"ESA hyporesponsiveness in CKD","volume":"8","author":"Wu","year":"2022","journal-title":"Kidney Dis (Basel)"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.3747\/pdi.2010.00299","article-title":"Hemoglobin variability with epoetin beta and CERA in PD patients","volume":"32","author":"Selby","year":"2012","journal-title":"Perit Dial Int"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.04920908","article-title":"Hemoglobin variability and mortality in nondialysis CKD","volume":"4","author":"Boudville","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007070728","article-title":"Hemoglobin variability in CKD anemia","volume":"20","author":"Kalantar-Zadeh","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.3773-24","article-title":"Roxadustat for treating anemia in patients with advanced chronic kidney disease not undergoing dialysis: A retrospective study","volume":"64","author":"Tamaki","year":"2025","journal-title":"Intern Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfad063c_5534","article-title":"HIFs and buts: a network meta-analysis of HIF PH inhibitors and ESAs in NDD-CKD patients with anemia comparing their safety and efficacy","volume":"38","author":"Warudkar","year":"2023","journal-title":"Nephrol Dialysis Transplant"},{"key":"B45","article-title":"Efficacy and safety of daprodustat compared with epoetin beta pegol in Japanese non-dialysis patients with anemia of chronic kidney disease: a 52-week, open-label, randomized controlled phase 3 trial [late-breaking clinical trial","author":"Kimura","year":"2019"},{"key":"B46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s41100-019-0221-z","article-title":"Long-term safety and effectiveness of a continuous erythropoietin receptor activator (CERA) in patients with renal anemia: a prospective, observational, multicenter study","volume":"5","author":"Tabata","year":"2019","journal-title":"Ren Replace Ther"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1810742","article-title":"Intravenous iron in patients undergoing maintenance hemodialysis","volume":"380","author":"Macdougall","year":"2019","journal-title":"N Engl J Med"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.83a.15065","article-title":"Anemia of CKD: treat it, but not too aggressively","volume":"83","author":"Nakhoul","year":"2016","journal-title":"Cleve Clin J Med"},{"key":"B49","unstructured":"KDOQI Clinical Practice Recommendations for Anemia in CKD\n          \n          \n          New York\n          National Kidney Foundation\n          \n          2006"},{"key":"B50","doi-asserted-by":"publisher","first-page":"52","DOI":"10.22270\/jddt.v10i3-s.4083","article-title":"Medication adherence and quality of life in CKD","volume":"10","author":"Varghese","year":"2020","journal-title":"J Drug Delivery Ther"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.3390\/nursrep15090314","article-title":"Factors contributing to non-adherence in hemodialysis","volume":"15","author":"Win","year":"2025","journal-title":"Nurs Rep"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1111\/nep.12940","article-title":"IV iron and ESA use in hemodialysis: a meta-analysis","volume":"22","author":"Roger","year":"2017","journal-title":"Nephrol (Carlton)"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S44646","article-title":"Impact of reduced dosing frequency on adherence","volume":"7","author":"Srivastava","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2006.12.011","article-title":"Intermittent dosing and adherence","volume":"28","author":"Kruk","year":"2006","journal-title":"Clin Ther"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.588202","article-title":"Simplifying anemia management in hemodialysis","volume":"27","author":"Schiller","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa065485","article-title":"Correction of anemia with epoetin alfa in chronic kidney disease","volume":"355","author":"Singh","year":"2006","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0907845","article-title":"A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease","volume":"361","author":"Pfeffer","year":"2009","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.03840907","article-title":"Novel erythropoiesis-stimulating agents: a new era in anemia management","volume":"3","author":"Macdougall","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(06)69120-4","article-title":"Novel strategies for stimulating erythropoiesis and potential new treatments for anaemia","volume":"368","author":"Macdougall","year":"2006","journal-title":"Lancet"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.2215\/cjn.03840907","article-title":"Pharmacokinetics of erythropoiesis-stimulating agents","volume":"17","author":"Macdougall","year":"2002","journal-title":"Nephrol Dial Transplant"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1185\/03007991003666652","article-title":"MIRACEL study: conversion to monthly IV CERA","volume":"26","author":"Fliser","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.14740\/jh862","article-title":"Monthly CERA vs weekly epoetin-beta","volume":"10","author":"Uriol-Rivera","year":"2021","journal-title":"J Hematol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1111\/1744-9987.12013","article-title":"Hemoglobin maintenance using IV CERA in Japan","volume":"17","author":"Hirai","year":"2013","journal-title":"Ther Apher Dial"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-016-0309-6","article-title":"Once-monthly CERA in HD-CKD: pooled phase III data","volume":"33","author":"Locatelli","year":"2016","journal-title":"Adv Ther"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-013-0063-y","article-title":"Darbepoetin to PEG-EPO dose conversion: AFFIRM study","volume":"30","author":"Choi","year":"2013","journal-title":"Adv Ther"},{"key":"B66","article-title":"Dose equivalence between CERA, darbepoetin, and epoetin","volume":"18","author":"Vega","year":"2014","journal-title":"Hippokratia"},{"key":"B67","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1186\/s41100-019-0221-z","article-title":"Long-term safety of CERA in renal anemia","volume":"5","author":"Tabata","year":"2019","journal-title":"Ren Replace Ther"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1159\/000368391","article-title":"Switching epoetin beta to CERA in HD patients","volume":"38","author":"Toida","year":"2015","journal-title":"Blood Purif"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/jch.14171","article-title":"Weekly vs biweekly IV CERA administration","volume":"23","author":"Kawai","year":"2021","journal-title":"J Clin Hypertens"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-020-01973-x","article-title":"CERA efficacy before and after PD initiation","volume":"25","author":"Fujimoto","year":"2021","journal-title":"Clin Exp Nephrol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1194919","article-title":"Interventions to promote medication adherence in India","volume":"11","author":"Tolley","year":"2023","journal-title":"Front Public Health"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/189404","article-title":"Cost-effectiveness of monthly CERA vs epoetin","volume":"2015","author":"Maoujoud","year":"2015","journal-title":"Anemia"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2021.27.12.1703","article-title":"Costs of ESA administration in ND-CKD","volume":"27","author":"Gauthier-Loiselle","year":"2021","journal-title":"J Manag Care Spec Pharm"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1600527","article-title":"Time spent on ESA administration in HD centers","volume":"22","author":"Chac\u00f3n-Araya","year":"2019","journal-title":"J Med Econ"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfad105","article-title":"The anaemia treatment journey of CKD patients: from epoetins to hypoxia-inducible factor-prolyl hydroxylase inhibitors","volume":"16","author":"Locatelli","year":"2023","journal-title":"Clin Kidney J"},{"key":"B76","unstructured":"Effective pharmaceutical cold-chain management\n          \n          \n          Binary Semantics"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.93584","article-title":"ESAs in CKD and cancer-related anemia","volume":"17","author":"Pothacamuri","year":"2025","journal-title":"Cureus"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14144863","article-title":"Effect of ESA types on hemoglobin variability in hemodialysis","volume":"14","author":"Kang","year":"2025","journal-title":"J Clin Med"}],"container-title":["Frontiers in Nephrology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1864394\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T14:53:39Z","timestamp":1788879219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneph.2026.1864394\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,8]]},"references-count":78,"alternative-id":["10.3389\/fneph.2026.1864394"],"URL":"https:\/\/doi.org\/10.3389\/fneph.2026.1864394","relation":{},"ISSN":["2813-0626"],"issn-type":[{"value":"2813-0626","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,8]]},"article-number":"1864394"}}